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STEM CELLS AND REGENERATION RESEARCH ARTICLE
Cooperative binding of AP-1 and TEAD4 modulates the balance
between vascular smooth muscle and hemogenic cell fate
Nadine Obier1, Pierre Cauchy1, Salam A. Assi1, Jane Gilmour1, Michael Lie-A-Ling2, Monika Lichtinger1,
Maarten Hoogenkamp1, Laura Noailles1, Peter N. Cockerill1, Georges Lacaud2, Valerie Kouskoff2 and
Constanze Bonifer1,*
ABSTRACT
The transmission of extracellular signals into the nucleus involves
inducible transcription factors, but how different signalling pathways
act in a cell type-specific fashion is poorly understood. Here, we
studied the regulatory role of the AP-1 transcription factor family in
blood development using embryonic stem cell differentiation coupled
with genome-wide transcription factor binding and gene expression
analyses. AP-1 factors respond to MAP kinase signalling and
comprise dimers of FOS, ATF and JUN proteins. To examine genes
regulated by AP-1 and to examine how it interacts with other inducible
transcription factors, we abrogated its global DNA-binding activity
using a dominant-negative FOS peptide. We show that FOS and
JUN bind to and activate a specific set of vascular genes and that
AP-1 inhibition shifts the balance between smooth muscle and
hematopoietic differentiation towards blood. Furthermore, AP-1 is
required for de novo binding of TEAD4, a transcription factor
connected to Hippo signalling. Our bottom-up approach
demonstrates that AP-1- and TEAD4-associated cis-regulatory
elements form hubs for multiple signalling-responsive transcription
factors and define the cistrome that regulates vascular and
hematopoietic development by extrinsic signals.
KEY WORDS: AP-1, TEAD4, Hippo signalling, Hematopoietic
specification, ESC differentiation, Signalling hubs
INTRODUCTION
The hematopoietic system has been a long-standing model for
general principles driving the transcriptional control of cell fate
decisions. During vertebrate embryonic development, the
emergence of definitive hematopoietic stem cells (HSCs) occurs
in the dorsal aorta (Medvinsky and Dzierzak, 1996), where cells of a
specialized hemogenic endothelium (HE) undergo an endothelial-
to-hematopoietic transition (EHT), lose adherence and, as newborn
HSCs, move to other sites of the embryo (Boisset et al., 2011; Eilken
et al., 2009; Kissa and Herbomel, 2010; Lancrin et al., 2009). Each
of these developmental transitions is regulated by an orchestrated
interplay of stage-specific transcription factors (TFs). For example,
SCL/TAL1 is required for the differentiation of HB cells to HE cells
(D’Souza et al., 2005; Lancrin et al., 2009), while RUNX1 is
essential for the EHT (Chen et al., 2009; Lancrin et al., 2009). These
TFs are connected to common and distinct target genes within a
dynamic transcriptional network (Goode et al., 2016). However,
although the roles of transcriptional regulators of hematopoietic
differentiation are beginning to be understood, it is less clear how
outside signals direct their activity and drive developmental stage-
specific gene expression.
The transmission of signals into the nucleus involves surface
molecules, such as receptor kinases, and inducible TFs at the
receiving end. Most inducible transcription factors are expressed in
multiple cell types and cooperate with tissue-restricted or other
inducible factors by binding to their cognate cis-regulatory elements
and altering gene expression in a signalling-dependent way. How
this process is coordinated and connected to the signalling network
is poorly understood and difficult to study, because signalling
pathways are highly dynamic, consisting of a myriad of different
components that operate in a cell type-specific fashion and
displaying multiple types of crosstalk. However, the sequences
that hard-wire the response to signals into our DNA are the same in
all cells. By identifying and studying the function of signalling-
responsive cis-regulatory elements and their interacting factors, we
are able to obtain a first insight into how signal transduction
processes are coordinated at the genomic level.
A paradigm for inducible transcription factors is the activator
protein 1 (AP-1) family of transcription factors, which are typical
targets ofMAP kinases, including ERK and JNK (Chang and Karin,
2001), that enhance their transcriptional activity through
phosphorylation (Angel et al., 1987; Karin and Smeal, 1992).
Generally, AP-1 factors promote gene expression, often in response
to stimuli such as growth factors. The AP-1 family comprises FOS
(FOS, FOSB, FOSL1, FOSL2) and JUN (JUN, JUNB, JUND)
proteins, but also ATF (ATFa, ATF-2, ATF-3) and JDP (JUN
dimerization proteins, JDP1, JDP2) proteins, all of which are
structurally and functionally related and act as dimers (Hess et al.,
2004; Jochum et al., 2001). While JUN family proteins can dimerize
with FOS, JUN, ATF and JDP proteins, FOS family proteins can
heterodimerize with only JUN family members. Several findings
point to an important role of this TF family at early stages of
hematopoietic specification: (1) work from our group found that
AP-1 motifs were enriched in open chromatin regions and
colocalized with TF-binding sites that were specific to HE cells
differentiated from mouse embryonic stem cells (ESCs) (Goode
et al., 2016; Lichtinger et al., 2012); (2) JUN knockout (KO) mice
die around the onset of HSC emergence (Eferl et al., 1999); (3) AP-1
was reported to play a role in Xenopus hematopoiesis (Lee et al.,
2012); (4) in zebrafish, the transcriptional co-repressor NCoR
silences Fos transcription and NCoR knockdown leads to inhibition
of HE formation (Wei et al., 2014); (5) AP-1 activation is involvedReceived 16 May 2016; Accepted 10 October 2016
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in the stimulation of engraftment of HSCs by epoxyeicosatrienonic
acids (Li et al., 2015); and (6) FOS has been identified as a crucial
factor together with GATA2, GFI1B and ETV6, in the
reprogramming of mouse embryonic fibroblasts (MEFs) to blood
cells (Pereira et al., 2013). However, none of these studies has
identified the global genomic targets responsible for these effects. In
addition, the expression of individual AP-1 family members, and
thus the dimer composition, varies depending on the cellular
context. Owing to the redundancy in this system, the analysis of the
general role of AP-1 factors has been difficult.
In this study, we gained a first insight into the role of the AP-1
factor family as a whole using in vitro differentiated mouse ESCs as
a model. During ESC differentiation, the first blood cells derive
from the hemangioblast (HB), a mesodermal cell type capable of
differentiating into vascular smooth muscle (SM), endothelial
and hematopoietic cells (Choi et al., 1998; Huber et al., 2004;
Kennedy et al., 1997; Stefanska et al., 2014). We expressed a
dominant-negative FOS (dnFOS) peptide from a doxycycline
(DOX)-inducible promoter and thereby abolished all AP-1 DNA-
binding activity (Olive et al., 1997). A surprising result of our
work was the finding that global AP-1 inhibition, in spite of the
near-ubiquitous expression of this factor family, is compatible
with hematopoietic specification, whereby in differentiating
hemangioblast cells FOS and JUN together bind to and activate a
core set of vascular effector genes. Importantly, we found that at
these genes AP-1 does not act alone but cooperates with TEAD4, a
mediator of the Hippo signalling pathway (Meng et al., 2016),
which we have previously shown to be essential for hematopoietic
specification (Goode et al., 2016). AP-1 inhibition abolished
TEAD4 binding at these genes, thus uncovering the mechanism of
the interdependency of the two signalling pathways. Our data
therefore show how inducible transcription factors are integrated at
the genomic level to form signalling hubs that modulate the balance
between cell fates.
RESULTS
Global AP-1 inhibition affects differentiation of ESCs via
hemangioblast to hematopoietic cells
The family of AP-1 transcription factors consists of diverse
members, most of which can heterodimerize and are likely to
compensate for each other’s absence. Therefore, we inhibited all
AP-1 activity directly and globally using a dominant-negative
version of FOS (dnFOS). This peptide contains a dimerization
domain for binding to JUN family proteins and an acidic extension
for blocking the DNA-binding domain of JUN, thus preventing both
the formation of JUN:JUN, JUN:ATF and JUN:FOS dimers, and
their binding to DNA (Olive et al., 1997). In order to examine a role
of AP-1 factors at different stages of hematopoietic specification, we
employed in vitro ESC differentiation that has previously been used
to recapitulate and investigate the different steps in hematopoietic
specification (Fig. S1A) (Goode et al., 2016; Lancrin et al., 2010).
We constructed an ESC line carrying a doxycycline (DOX)-
inducible Flag-tagged dnFOS allele (Fig. 1A) (Kyba et al., 2002).
We ensured that the peptide inhibited AP-1-driven gene activation
in a luciferase assay (Fig. S1B), that its expression was tightly
regulated (Fig. S1C) and that the protein was present in every cell
(Fig. S1D), and demonstrated that induction of the construct indeed
blocked JUN binding to DNA in a genome-wide fashion (Fig. 1C
and Fig. S1E).
Several members of the AP-1 family are expressed at one or more
stages of in vitro ESC differentiation into blood (Fig. S1F). To be
able to study the molecular mechanism of AP-1 function in detail,
we first had to examine at which stages AP-1 activity was crucially
required. To this end, we induced dnFOS by addition of DOX at
distinct time points of ESC differentiation.
As outlined in Fig. 1B (and Fig. S1A), ESCs were differentiated
into embryoid bodies (EBs) and after 3.75 days HB cells were
enriched by purifying cells positive for the VEGF receptor (FLK1+).
Subsequently, FLK1+ cells were kept for up to 4 days in the presence
of IL-6 and VEGF under blast culture (BC) conditions where they
differentiated to vascular smooth muscle (SM) cells or successively
to the following cell types: (1) early hemogenic endothelial cells
(HE1,KIT+TIE2+CD41−), (2) late hemogenic endothelial cells fully
committed to blood but still adherent (HE2, KIT+TIE2+CD41+) and
(3) floating hematopoietic progenitor cells that have undergone the
EHT (HP, KIT+TIE2−CD41+). The inhibition of AP-1 activity
during the establishment of HB cells by adding DOX to EB cultures
led to increases in total cell number within EB cultures and in the
proportion of FLK1+ cells (Fig. S1G,H). To examine the role of AP-
1 at later differentiation stages, we expressed dnFOS during BC by
either inducing freshly purified FLK1+ cells (4 days of induction) or
adding DOX subsequently at day 1, day 2 or day 3 of BC (Fig. 1D).
After 4 days, complete cultures and floating cells (containing
progenitor cells) were assessed for cell count and phenotypic
composition, respectively. Despite no significant change in overall
cell number (Fig. 1E, left panel), complete blast cultures contained a
higher proportion of KIT+ cells (Fig. S1I,J) and HE2 cells after
dnFOS induction (Fig. 1E, right panel; Fig. S1K). This effect was
strongest when AP-1 was inhibited at the very beginning of blast
culture. Moreover, we found that an early block of AP-1 (4 days
DOX treatment) led to a significant increase in the amount of
floating cells (Fig. 1F, left). However, myeloid commitment of such
cells, as measured by CD11b surface marker expression, was
significantly diminished (Fig. 1F, right panel; Fig. S1L). Moreover,
when AP-1 was inhibited only transiently in the first 24 h of blast
culture with subsequent DOX washout and culture medium
replacement, numbers of floating cells at day 3 were increased to
the same extent as observed after a continuous 3-day treatment period
(Fig. S1M). By contrast, proportions of CD11b+ cells were decreased
to a lesser extent when DOX was withdrawn after 1 day (Fig. S1N).
Together, these results suggest that AP-1 is involved in
modulating the transitions of several distinct stages of blood
development, supporting or impairing respective cell fates.
However, in spite of the near-ubiquitous expression of this factor
family, global AP-1 inhibition does not lead to gross disturbances in
blood cell specification.
Inhibition of AP-1 at the hemangioblast stage shifts the
balance between vascular and blood cell development
Having shown that blocking all AP-1 activity is compatible with
differentiation, we next examined whether this factor was involved
in regulating cell fate. To this end, we studied the differentiation of
HB cells by analysing complete blast cultures ±DOX after 1 and
2 days of induction, as well as floating cells after 3 days (Fig. 2A).
Although cell numbers at day 1 were unaffected by AP-1 inhibition,
we measured a significant reduction in the proportion of SM cells as
assessed by intracellular flow cytometry using three different SM
cell markers: SMA, SM22α and calponin (Fig. 2B,C and Fig. S2D).
Endothelial marker expression was unaltered with the exception of a
slight increase in FLK1+ cells in DOX-treated cultures (Fig. S2E).
Further, when analysing day 2 blast cultures we observed
significantly increased cell numbers (Fig. 2D), with overall no
difference in apoptosis (Fig. S2A). DOX-induced cells showed
higher S- and G2/M-cell cycle phase contribution and expressed
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significantly lower levels of the negative cell cycle regulator gene
Cdkn2a (p16) (Fig. S2B,C), which explains the enhanced
proliferation. As in the time course experiment (Fig. 1E), the
frequency of HE2 cells was also significantly increased when AP-1
was inhibited for 2 days only (Fig. 2F, Fig. S2H), whereas SM cell
proportions were significantly lower (Fig. 2E, Fig. S2F) and
Fig. 1. See next page for legend.
4326
STEM CELLS AND REGENERATION Development (2016) 143, 4324-4340 doi:10.1242/dev.139857
D
E
V
E
LO
P
M
E
N
T
endothelial cells remained unaffected (Fig. S2G). These results
demonstrate that the gain of hematopoietic HE2-type cells was
paralleled by a loss of SM cells. The number of non-adherent,
floating cells that had undergone the EHT after a 3-day culture and
dnFOS-induction period was significantly increased by more than
fourfold when compared with untreated cultures (Fig. 2G). We next
characterized these cells by surface marker flow cytometry. The
analysis revealed that the proportions of KIT+, CD41+ and CD71+
cells within floating cells emerging upon AP-1 inhibition were
comparable with untreated cells, demonstrating that hematopoietic
commitment had happened (Fig. S2I,J). However, although floating
cells of untreated cultures showed expression of CD45 and CD11b,
indicating their maturation and myeloid commitment, DOX-treated
cells failed to express these markers and appeared to be blocked in
differentiation (Fig. S2I,J and Fig. 2H). We further noticed a slight
but significant increase in CD71high cells upon AP-1 inhibition,
which was reported to represent a population of primitive
erythroblasts (Chao et al., 2015). To test whether floating cells
derived from dnFOS-induced cultures have the potential to form
normal colony when compared with untreated cultures, we
performed colony-forming assays in the absence of DOX.
Overall, we detected similar colony formation capacity, with
similar numbers and sizes of colonies (Fig. 2I). Although the
myeloid commitment in dnFOS-induced blast cultures was
inhibited (Fig. 2H and Fig. S2I,J), progenitor cells derived from
DOX-treated blast cultures were able to give rise to myeloid cell-
containing CFU-GM- and CFU-Mix-type colonies when DOX was
withdrawn, with a slight bias towards colonies with erythroid
contribution (BFU-E and CFU-Mix). Together, these experiments
demonstrate that AP-1 inhibition by dnFOS in differentiating HB
cells shifts the balance between smooth muscle and hemogenic cell
fates and reversibly blocks myeloid commitment, suggesting a dual
role of AP-1 in this developmental pathway, promoting both smooth
muscle and myeloid cell types.
AP-1 inhibition does not alter global transcriptional
networks but affects expression of key stage-specific genes
To gain insight into how AP-1 regulates cell fate, we focused on the
differentiation of HB cells into SM and HE cells. We investigated
the transcriptional changes induced by blocking AP-1 activity using
microarray gene expression analysis with RNA extracted from
freshly purified FLK1+ HB cells, complete blast cultures after 5 h
and 1 day of induction, as well as from FACS-sorted SM, HE1, HE2
and HP cells at day 2 of blast culture (Fig. 3A, Fig. S3A,B).
Principal component analysis revealed that samples of the same cell
type clustered closely together with or without dnFOS induction,
indicating that AP-1 inhibition did not globally alter the gene
expression patterns of induced cells (Fig. 3B, Fig. S3C). However,
we identified a number of genes that were at least twofold
differentially expressed (Fig. 3C, Fig. S3D and Table S1).
Consistent with AP-1 generally functioning as an activator, we
found more downregulated than upregulated genes. K-means
clustering of differentially expressed genes in the sorted cell
populations SM, HE1, HE2 and HP (Fig. 3D) established a total of
15 clusters, each containing genes with similar expression fold
change patterns over the four cell types. We also evaluated their
gene ontology (GO) terms (Table S2 and Fig. S3E). Clusters 3, 4
and 1 retrieved genes that were expressed at lower levels in HE2 and
HP cells such as the myeloid regulators Csf1r, Sfpi1 (Pu.1) and
Cebpa, which was in line with the reduced number of CD11b+ cells
observed in DOX-treated blast cultures. Genes upregulated in HP
cells (cluster 13) were associated with erythrocyte differentiation
and clusters 12 and 6 comprised genes that were downregulated in
SM and HE1 cells, e.g. Lamc2, Myo1e, Flnb, Serpine1 or Wt1
(Fig. 3D,E and Fig. S3G). These gene products are associated with
vascular cell types (GO terms Fig. S3E and Duim et al., 2015) and
their decreased expression may reflect the lower contribution of
vascular SM cells upon dnFOS-induction. We also found a group
of HSC-related genes, including Hoxb4, Bmi1 and Gfi1, that
were expressed at higher levels in the absence of AP-1 activity
(Fig. 3D,E, Fig. S3G, with manual validations shown in Fig. S3F).
In SM and HE1 cells, blocking AP-1 activity affected vascular
genes, whereas at later stages in HE2 and especially HP cells
myeloid gene expression was reduced. In summary, despite their
widespread expression and promiscuous involvement in multiple
signalling processes, the absence of AP-1 during cell differentiation
does not deregulate large sets of genes, but influences cell fate
decisions by impacting on a limited set of key stage-specific
regulator and effector genes.
AP-1 is required for the transient activation of vascular genes
in the hemogenic endothelium
The most common AP-1 complex consists of FOS and JUN
proteins. To identify targets for these two factors, we performed
ChIP-seq in day 1 blast culture cells, which mostly comprise SM
cells with the rest being HE1/2 cells (Fig. 4A, Fig. S4A). As AP-1
proteins only transiently bind to their templates (Biddie et al., 2011),
we employed a double-crosslink procedure that greatly enhanced
ChIP signals (see Materials and Methods). We found a total of 4889
and 2999 binding events for FOS- and JUN-binding sites,
respectively, with the majority of them being at distal regulatory
elements at either intronic or intergenic sites (Fig. 4B, Table S3,
Fig. S4B). The integration of the two replicate JUN ChIP-
experiments shown here and in Fig. 1C revealed that more than
78% of the JUN peaks shown in Fig. 4 overlapped (Fig. S4C). The
GO terms associated with genes co-bound by FOS and JUN from
both replicates produced an almost identical list of terms and P
values (Fig. S4D).
Approximately 40% of JUN peaks overlapped with FOS-binding
sites, whereas 25% of FOS peaks overlapped with JUN, suggesting
that JUN and FOS interacted with different partners at unique sites.
Fig. 1. AP-1 inhibition affects differentiation of ESCs to hemangioblast, to
hemogenic and to hematopoietic cells. (A) Schematic representation of the
targeted HPRT-gene locus of the DOX-inducible dnFOS-expressing A17 2lox
mouse ESC line (dnFOS ESCs). (B) Overview of the in vitro differentiation of
ESCs to blood cells and the corresponding time course of dnFOS induction
(DOX). (C) JUN ChIP-seq in uninduced and DOX-treated dnFOS cells. FLK1+
dnFOS cells were cultured under blast culture conditions for 1 day±1 µg/ml
DOX. Cells of complete cultures were double crosslinked and chromatin was
used for JUN ChIP followed by genome-wide sequencing. The JUN ChIP-seq
signal in the untreated dataset and the corresponding signal detected in the
DOX dataset are shown. (D) Schematic overview of the DOX-induction time
course approach during blast culture. FLK1+ dnFOS cells were cultured for
4 days under blast culture conditions. Cells were either left untreated (4 days
untreated) or DOX was added from start of culture (for 4 days=4 days DOX),
at day 1 (3 days DOX), day 2 (2 days DOX) or day 3 (1 day DOX) of culture.
At day 4, complete cultures and floating cells were analysed for cell
numbers and surface marker profiles by flow cytometry. (E) Total cell counts
(left) and a representative CD41-/Tie2-specific flow cytometric analysis of
pre-gated cKitpos cells (right) of day 4 complete blast cultures that were either
left untreated or DOX-treated for 1 day, 2 days, 3 days or 4 days (data are
mean±s.d., n=3). (F) Total cell counts (left) and a representative CD11b-
specific flow cytometric analysis (right) of day 4 floating cells derived from
dnFOS blast cultures that were either left untreated or DOX treated for 1 day,
2 days, 3 days or 4 days (data are mean ±s.d., n=3).
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In total, we identified 1227 genomic sites that were co-bound by
FOS and JUN (Fig. 4C). Next, we annotated the closest genes to
FOS and JUN peaks, intersected both gene populations and
identified 910 genes that were bound by JUN only, 2190 bound
by FOS only and 1388 genes that were annotated to both FOS and
JUN peaks (Fig. 4D, Table S4). To examine whether the different
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binding configurations of JUN and FOS regulate different sets of
genes, we further dissected these 1388 genes into those where FOS
and JUN bound at identical sites (FOS:JUN co-bound, 1042 genes)
and those where FOS and JUN bound at different sites (FOS and
JUN distinct, 346 genes) (Fig. 4E, Table S4). Exemplary genome
browser screen shots for these different patterns are shown in
Fig. 4F. Gene ontology analysis revealed that FOS alone and JUN
alone bound to genes associated with phosphorylation, metabolism
and signalling (Fig. 4G). Interestingly, in contrast to these more
general GO terms, FOS and JUN bound to heart- and muscle-linked
genes; moreover, FOS:JUN dimers highly significantly co-bound
vascular genes (Fig. 4G, lower right panel), suggesting a direct
regulation of the vascular rather than the hematopoietic cell fate.
We next integrated FOS- and JUN-binding patterns with
transcriptional changes ±DOX for day 1 blast culture, i.e. the time
point of FOS and JUN ChIP-seq, by performing gene set
enrichment analyses (GSEA). We found a high correlation
between FOS or JUN binding and downregulated gene expression
upon dnFOS induction (Fig. S5A), showing that both factors have
largely activating roles. Next, we investigated the general pattern of
expression of genes annotated to JUN only, FOS:JUN and FOS only
binding events (Fig. S5B, left panel) all of which generally showed
lower expression after 1 day of dnFOS induction than in control
cells. This effect was strongest for FOS:JUN co-bound genes.
Focusing on transcriptional changes of AP-1 target genes occurring
during transitions of distinct developmental stages in the absence of
DOX, we observed that AP-1 target genes were generally
upregulated from FLK1+ to SM and from FLK1+ to HE1 cells,
followed by a downregulation from HE1 to HE2 cells, but did not
further change expression during the transition from HE2 to HP
cells (Fig. S5B, right panels). Together with the GO analysis
(Fig. 4G), this finding suggests that AP-1 is involved in a transient
induction of vascular (endothelial and smooth muscle-related)
genes in HB-derived cells, which are then downregulated during the
EHT.
We next analysed the dynamic activity of all FOS:JUN co-bound
genes in more detail by conducting k-means clustering of
expression patterns in control FLK1+ cells, FLK1+ cells after 5 h
and 1 day of BC, and in day 2 SM, HE1, HE2 and HP cells (Fig. 5A,
Table S5). This analysis revealed seven gene clusters each with
similar expression patterns during the differentiation of HB to HP
cells. We then compared the averaged expression levels of each of
the seven clusters during unperturbed differentiation with averaged
expression levels of dnFOS-induced cells (Fig. 5B). Specific
differences of expression levels between induced and control cells
were apparent only in clusters 5 and 6, which contain 203 genes that
are normally highly induced in day 1 blast culture, SM and HE1
cells. Sixty-eight of these genes were expressed at significantly
lower levels when AP-1 was blocked (Table S6), among them we
identified collagens (Col1a1, Col4a1, Col5a1) and Bmp1 (the
metalloprotease that supports collagen maturation by cleaving
procollagens), vascular growth factors (Vegfa, Pdgfc, Hbegf, Ctgf ),
signalling ligands (Bmp2, Tgfb), genes encoding integrin ITGA11
and laminin LAMC2, and the transcription factor WT1, which was
recently shown to be involved in angiogenesis (Duim et al., 2015;
Katuri et al., 2014). These findings strongly suggest that during HB
cell differentiation, AP-1 and in particular the FOS:JUN complex,
activates a specific set of genes in SM and HE1 cells that are closely
linked to and important for blood vessel formation. In the
subsequent transition of HE1 cells to HE2 cells, i.e. cells that are
fully committed to blood, these genes are downregulated and remain
low in HP cells.
AP-1 is required for de novo binding of the Hippo-signalling
regulator TEAD4 at specific binding sites
The developmental stage-specific response to AP-1 inhibition
indicated that these factors interact with cell type-specific sets of
cis-regulatory elements. In order to identify additional TFs binding
to these elements, we performed a de novo motif discovery
analysis of FOS only, JUN only and FOS:JUN co-bound genomic
sequences. For each of the three groups, the AP-1 consensus
sequence was retrieved as top hit as expected (Fig. 5C, Fig. S5C).
The CREB motif was also highly enriched and specific to JUN
only peaks, reflecting the ability of JUN, but generally not FOS, to
dimerize with ATF proteins (Fig. 5C, Fig. S5C) (Hai and Curran,
1991; Karin et al., 1997; van Dam and Castellazzi, 2001). A
striking result from our motif analysis was the co-association of
TEAD motifs within all FOS and JUN peaks (Fig. 5C). Moreover,
in a motif co-occurrence clustering analysis computing enrichment
against background colocalization frequencies, we found a close
colocalization of AP-1 and TEAD motifs in FOS- and JUN-
binding sites (Fig. S5D). The TEAD family of transcription factors
contains four members, TEAD1-TEAD4, all of which share the
same consensus sequence and are the downstream effectors of
Hippo signalling (Meng et al., 2016). In the absence of Hippo
signalling TEAD factors bind to DNA, but can activate gene
expression only together with co-activators such as YAP, VGLL
or p160 (Pobbati and Hong, 2013). Active Hippo signalling leads
to phosphorylation of LATS1/2 by MST1/2, and to subsequent
phosphorylation of YAP. Consequently, phospho-YAP is
restricted to the cytoplasm and fails to activate TEAD-bound
genes.
Recent reports described the genomic colocalization of AP-1 and
TEAD proteins in cancer cell lines (Diepenbruck et al., 2014; Liu
Fig. 2. AP-1 inhibition at the hemangioblast stage enhances cell
proliferation and shifts the balance between vascular and blood cell
development. (A) Experimental setup: dnFOS ESCs were differentiated for
3.75 days as EBs. FLK1+ HB cells were purified and subsequently cultured
±1 µg/ml DOX under blast culture conditions for 1 day, 2 days or 3 days before
either complete cultures (day 1 and day 2) or floating cells (day 3) were
analysed. (B) Fold changes of cell numbers at day 1 compared with day 0
(=seeded cell numbers) of complete dnFOS blast cultures with and without
DOX induction (data are mean ±s.d., n=5, t-test). (C) Complete day 1 dnFOS
blast cultures with and without DOX induction were assessed by intracellular
SM cell-specific calponin staining (data are mean ±s.d., n=4, t-test, *P=0.019).
A representative flow cytometric analysis and the summary of three
experiments is shown (for other smooth muscle cell markers and statistical
summary, see Fig. S2). (D) Fold changes of cell numbers at day 2 compared
with day 0 (=seeded cell numbers) of complete dnFOS blast cultures with and
without DOX induction (data are mean ±s.d., n=5, t-test). (E) Complete day 2
dnFOS blast cultures with and without DOX induction were assessed by
intracellular SM cell-specific calponin staining. (data are mean ±s.d., n=3,
t-test, *P=0.038). A representative flow cytometric analysis and the summary of
three experiments is shown (for other smooth muscle cell markers and
statistical summary, see Fig. S2). (F) The cell composition of complete day 2
dnFOS blast cultures ±DOX was analysed by flow cytometry using antibodies
against KIT, TIE2 and CD41. A representative contour plot of pre-gated KIT+
cells is shown. (G) The number of dnFOS floating cells with and without DOX
induction at day 3 per FLK1+ cell that was seeded at day 0 (data aremean±s.d.,
n=4). (H) Floating cells of day 3 dnFOS blast cultures with and without DOX
induction were harvested and stained with a CD11b-specific antibody prior to
flow cytometric analysis. Representative contour plots are shown. (I) Floating
cells derived from day 3 dnFOS blast cultures with and without DOX induction
were harvested and plated into methylcellulose medium for a hematopoietic
colony assay (in the absence of DOX). After 10 days, colonies were counted
and classified as BFU-E, CFU-Mix and CFU-GM (data are mean ±s.d., n=3).
Examples of colonies are shown at the bottom.
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et al., 2016; Verfaillie et al., 2015; Zanconato et al., 2015); however,
how these two factors cooperate at specific genes was not studied.
Thus, we investigated TEAD4 occupancy upon blocking AP-1
DNA binding by performing ChIP-seq in day 1 blast culture
cells±dnFOS (Fig. S1E, Fig. 6A). For untreated cells, we obtained a
total of 21,422 TEAD4 peaks, while the number of peaks for
DOX-treated cells was almost halved (11,721 peaks, Fig. 6B and
Fig. S6A). The decrease in peak numbers did not affect the overall
genomic distribution: most of TEAD4 binding was still detected in
distal intergenic or intronic elements (Fig. S6A). De novo motif
discovery analysis showed that, with or without AP-1 inhibition, the
TEAD motif was the top hit (Fig. 6C). However, AP-1 motifs in the
DOX-treated sample were undetectable, indicating that, upon
dnFOS expression, TEAD4 was no longer binding to sites
containing AP-1 motifs (Fig. 6C, right panel). To substantiate this
finding, we compared all TEAD4 peaks derived from treated and
untreated cells, and ranked them according to the fold change of
ChIP-seq signal intensity (Fig. 6D), which revealed three classes of
TEAD4-binding sites (Table S7): class 1, comprising peaks that
were specific to untreated cells and lost upon AP-1 inhibition (6787
sites, 30.6%); class 2, representing a shared class of TEAD4 binding
that was not affected by dnFOS induction (14,404 sites, 65.1%); and
class 3, containing a relatively small number of TEAD4 peaks that
were gained (950 sites, 4.3%). The TEAD motif was found
throughout all three classes, whereas the AP-1 motif was specific to
class 1 peaks (Fig. 6D shows the motif heatmap and average
profiles). When annotating the closest genes and analysing their
expression fold change±DOX in day 1 blast culture, we found
significantly lower expression only in class 1 genes, showing that
the interaction between TEAD4 and AP-1 is required for high-level
expression (Fig. 6D, right panel and box plot).
To investigate how TEAD4 binding was associated with JUN/
FOS binding, we compared the ChIP-seq signals for FOS and JUN,
as well as the previously identified FOS:JUN co-bound, JUN-only
and FOS-only peaks using the same ranking of TEAD4 peaks
(Fig. 6E). The majority of FOS- and JUN-binding events was
contained in class 1 peaks, particularly FOS:JUN co-bound sites
overlapped strongly with TEAD4 sites that were lost upon AP-1
inhibition. Intersecting the 203 FOS:JUN co-bound genes from
cluster 5 and 6 (Fig. 5B) with class 1 TEAD4-bound genes, revealed
that 175 of them, i.e. 86%, showed loss of TEAD4 binding upon
dnFOS expression. Exemplary genome browser screen shots of
some of these gene loci are shown in Fig. 6F and Fig. S6B. We
further narrowed this gene population down to a total of 64 genes
sharing the following features: transiently expressed during HB
differentiation, co-bound by FOS:JUN, AP-1 dependently bound by
TEAD4 and expressed at significantly lower levels upon dnFOS
induction (Table S6). A high proportion of FOS and JUN peaks
overlapped with TEAD4 binding without DOX (Fig. S6C). We
found that the average TEAD4 ChIP-seq signal centred on such
FOS or JUN peaks was reduced by more than twofold (Fig. S6D)
upon AP-1 inhibition, again suggesting that a defined class of
TEAD4-binding sites was AP-1 dependent.
In order to understand the dynamics of TEAD4 binding in
development, we analysed TEAD4 ChIP-seq data in FLK1+ HB
cells that we had published recently (Goode et al., 2016) and in
addition generated a TEAD4 ChIP-seq dataset for purified HE1
cells (KIT+Tie2+CD41−), 75% of which overlapped with that of
day 1 BC (Fig. S6A,E,G,H). In freshly purified FLK1+ HB cells,
TEAD4 binding was already established at class 2 sites, but not at
class 1 sites (Fig. S6E,G), which were specific for the HE stage. In
summary, these analyses reveal that during the differentiation of HB
cells into the HE cells, TEAD4 de novo binding occurs at cis-
regulatory elements associated with a subset of vascular genes and
that this binding is dependent on AP-1, suggesting a recruiting role
for AP-1.
AP-1- and TEAD-bound regions colocalize with occupied
binding motifs for multiple inducible transcription factors in
open chromatin of hemogenic endothelium cells but not
thereafter
We have recently shown that the interaction between YAP and
TEAD factors is required for the differentiation of hematopoietic
cells from FLK1+ cells purified from ESCs and mouse embryos but
not in HP cells. This was accompanied by an activation of Hippo
signalling, leading to the absence of TEAD and YAP in the nucleus
of HP cells (Goode et al., 2016). The analysis presented here shows
that on average all genes bound by TEAD4 showed similar
expression patterns during HB differentiation: a strong induction
from FLK1+ to SM and from FLK1+ to HE1 cells (Fig. S6F). GO
analysis showed that all three classes of TEAD4 sites were
associated with genes involved in cell adhesion and
vasculogenesis (Fig. S6I). However, all of these genes were
strongly downregulated from HE1 to HE2 cells, and expression
did not change in HP cells, suggesting that AP-1 cooperates with
TEAD prior to, but not after, the EHT. We tested this idea by
performing deep DNaseI sequencing in FACS-purified HE1
(KIT+TIE2+CD41−) and HP (KIT+TIE2−CD41+) cells. We
obtained 68,691 DNaseI hypersensitive sites (DHSs) for HE1
cells and 63,712 DHSs for HP cells [44,216 of them were shared
between the two samples (Fig. S7A,B)]. De novo motif discovery
analysis revealed that ETS, GATA, AP-1, TEAD and SOX motifs
were enriched in HE1 open chromatin regions, whereas motifs for
the hematopoietic transcription factors RUNX, ETS, CEBP and
MEIS, and also AP-1 motifs, were found in HP-specific DHSs
(Fig. 7A,B). Upon ranking of the fold change of the union of HE1
and HP DHSs, we identified specific patterns of motif distribution:
TEAD, SOX and GATA motifs were distinct from HE1-specific
DHSs, whereas RUNX and CEBP motifs were characteristic of HP-
unique DHSs (Fig. 7C, Fig. S7C). The AP-1 motif was found in
both HE1-specific and HP-specific DHSs, but not at shared sites,
Fig. 3. dnFOS induction causes distinct changes to global gene
expression programmes. (A) Experimental setup: dnFOS ESCs were
differentiated for 3.75 days as EBs. FLK1+ HB cells were purified and
subsequently cultured with and without 1 µg/ml DOX under blast culture
conditions for 5 h, 24 h or 48 h. Freshly purified FLK1+ cells (=0 h), 5 h and
1 day cultures with and without DOX induction were used directly for RNA
extraction, whereas day 2 cultures with and without DOX induction were sorted
by FACS into pure populations of SM, HE1, HE2 and HP cells prior to RNA
extraction. RNA was used for genome-wide gene expression arrays. Each
population was analysed in duplicate. (B) Principle component analysis with
three components for all 13 indicated cell types. (C) Pairwise comparison of
microarray data from untreated and DOX-treated cells. The numbers of
significantly (at least twofold) up- and downregulated genes are shown. The
numbers at the top indicate the genes that are upregulated (DOX versus
untreated samples) for each time point, the numbers on the left represent
genes that are downregulated (DOX versus untreated samples) for each time
point. The numbers within the table show how many of the up-/downregulated
genes at each time point are also mis-regulated (green, down; red, up) at other
time points. (D) SM, HE1, HE2 and HP samples with and without DOX
induction were used for k-means clustering by fold change of genes that
change expression at least twofold upon dnFOS induction. For the resulting 15
clusters of genes, a heatmap was generated and some genes of interest are
indicated next to their respective cluster. (E) Expression values of exemplary
genes over the course of differentiation with and without DOX induction based
on data from microarrays. Individual replicates for each sample are depicted.
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Fig. 4. During hemangioblast commitment, FOS and JUN bind to genes involved in blood vessel development, cell adhesion and cell signalling.
(A) Experimental setup: Bry-GFPWT ESCs (JUN) or dnFOSESCs (FOS) were differentiated as indicated. FLK1+ cells were purified and cultured for 1 day under
blast culture conditions in the absence of DOX. Cells of complete cultures were double crosslinked as described in theMaterials andMethods, and chromatin was
used for FOS and JUN ChIP followed by genome-wide sequencing. (B) Binding and genome localization statistics of FOS and JUN peaks within the mouse
genome. (C) Overlap of peaks detected in FOS and JUN ChIP-seq datasets. (D) Overlap of genes associated with FOS and JUN peaks. (E) Overlap of genes
associated with intersecting FOS and JUN peaks (C) and genes associated with FOS- and JUN-binding events (D). (F) Representative genome browser screen
shots of FOS and JUN ChIP-seq at the Lamc2 and Nrp1 loci. (G) Gene ontology analysis of genes bound by FOS only, JUN only, FOS:JUN co-bound and bound
by FOS and JUN distinctly. The top GO terms and the corresponding −log P-value are shown.
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again highlighting the different function of these binding sites in
endothelial and hematopoietic cells. When plotting FOS and JUN
ChIP-seq signal of day 1 blast culture cells using the same ranking,
the highest signal was obtained in HE1-specific DHSs (Fig. S7C),
concordant with binding of AP-1 in HE1 cells. We then annotated
these binding sites to the promoters of the closest genes, calculated
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fold changes in expression for developmental transitions and plotted
the resulting heatmaps in the same ranking (Fig. 7C, right panel).
Generally, genes annotated to HE1-specific DHSs were upregulated
from FLK1+ to HE1 and downregulated from HE1 to HE2, whereas
their expression did not change from HE2 to HP. By contrast, genes
annotated to HP-specific sites showed a gradual upregulation
throughout all transitions from HB to HP. Furthermore, HP-specific
sites were associated with AP-1, RUNX and CEBP motifs, as seen
with FOS binding in mast cells (Calero-Nieto et al., 2014) and with
reduced transcription in HP cells upon dnFOS induction (Fig. 7C,
Fig. S7C). These observations support our hypothesis of AP-1
playing a role during the differentiation of HP cells to
myelomonocytic cells. However, TEAD appears to be involved
only in a HE1-specific context.
To examine the interaction between TEAD4 and AP-1 at base-
pair resolution, we performed digital footprinting analysis on our
DNaseI-seq data using theWellington algorithm (Piper et al., 2013),
and identified 70,522 and 53,964 regions in HE1 and HP cells that
were protected from DNaseI digestion, respectively (Fig. S7D).
Interestingly, the overlap between those was found to be not
significant (P=1), denoting a markedly different repertoire of
occupied TF-binding sites between the two stages. Both AP-1 and
TEAD motif-containing footprints were enriched in HE1 cells, and
occupancy of these motifs in HE1 cells was strongly reduced in HP
cells (Fig. S7E-H). Moreover, when centred on FOS and JUN ChIP-
seq peaks of day 1 blast culture, AP-1 motifs were preferentially
occupied in HE1 cells rather than HP cells (Fig. S7I), and were
associated with class 1 genomic sites (see Fig. 6D, AP-1-dependent
TEAD4 sites) for HE1 but not for HP (Fig. S7J). This assay also
allowed us to investigate the co-occupancy of other transcription
factor binding motifs with AP-1 and TEAD by clustering HE1-
footprinted motifs using bootstrapping analysis, which determines
the significance of co-clustering motifs within 50 bp of DNA. We
found a significant co-occurrence of occupied AP-1 and TEAD
motifs together with occupied motifs for other signalling-inducible
transcription factors such as SMAD, NFAT, CREB and TCF,
together with motifs for tissue-specific factors such as SOX and
GATA (Fig. 7D). Our results are supported by previous reports
describing a co-association of GATA and AP-1 in mature vascular
cells (Linnemann et al., 2011). By contrast, in HP cells, occupied
motifs for the hematopoietic transcription factors ETS, E-Box
(TAL1), RUNX- and CEBP predominantly clustered together
(Fig. S7K). Importantly, at co-occurring AP-1 and TEAD
footprinted motifs in HE1 cells, we found a bias towards a
defined oriented distance between both motifs with a 7 bp spacing
(Fig. 7E, Fig. S7L). This composite motif likely indicates direct
interaction between AP-1 and TEAD, as was identified from other
composite motifs previously (Chen et al., 1998; Cockerill et al.,
1995; Hollenhorst et al., 2009). In conclusion, these analyses show
that AP-1 and TEAD co-occupy a subset of genomic sites that are
accessible in HE1 cells but inaccessible in HP cells. Genes
associated to these elements are transiently activated from HB to
HE1 commitment but downregulated in HE2 and HP cells.
In summary, we propose a model in which AP-1 (FOS:JUN)
promotes the differentiation of vascular smooth muscle cells and
also binds to vascular genes in the hemogenic endothelium
(Fig. S8). During the transition from HB to HE1 cells, AP-1 is
needed for the transient induction of such genes, which are
subsequently downregulated when cells further differentiate to
blood-committed cells. A substantial proportion of these genomic
sites is co-occupied by the Hippo signalling-related TF TEAD4 and
we show that AP-1 is required for its de novo binding to these
elements. Although AP-1 is also important later for the maturation
of HP cells, it no longer co-localizes with TEAD4 at this
developmental stage. Altogether, our study highlights the
versatility of the ESC differentiation system to dissect the
molecular mechanism of specific knockout phenotypes that would
otherwise not be amenable to biochemical studies.
DISCUSSION
Inhibition of AP-1 activity shifts the balance between
vascular and hematopoietic cell fates
By identifying and studying the function of genomic regions bound
by signalling-responsive TFs we can obtain a first mechanistic
insight into how such processes are coordinated and which
signalling processes are involved. Here, we have used such a
bottom-up approach to study the function of the AP-1 transcription
factor family in hematopoietic specification. Our results uncover a
role for AP-1 in the establishment of the smooth muscle and
vascular program from hemangioblast cells, identify the genes
involved in this process and pinpoint the developmental stage at
which this occurs. Lineage-tracing experiments demonstrated that
SM cells and HE cells develop independently of each other fromHB
cells (Stefanska et al., 2014). We hypothesize that the impaired
induction of the vascular gene expression program in the hemogenic
endothelium after AP-1 inhibition leads to an imbalanced cell fate
decision towards blood-committed cells and consequently to more
HP cells. This is consistent with a previous report, stating that
repression of arterial/vascular genes in HE is sufficient for
hematopoietic fate acquisition (Lizama et al., 2015). Runx1
expression is not affected by dnFOS expression (Table S1) and
thus hematopoietic progenitor cells undergo the EHT and
upregulate the RUNX1-dependent CD41 marker (Lie-A-Ling
et al., 2014). In the presence of DOX, the cells cannot mature to
CD45+ and CD11b+ cells, indicating that further differentiation is
blocked. However, in the absence of dnFOS they resume their
normal differentiation behaviour and form different types of
colonies, indicating that this block is reversible.
In addition to changes in the differentiation pattern, we observed
enhanced proliferation throughout ESC differentiation in the
presence of dnFOS. Cdkn2a and Cdkn2b, which encode the
negative cell cycle regulators p16INK4a and p15INK4B,
respectively, were bound by AP-1 and expressed at lower levels
after AP-1 inhibition. Both Cdkn2a and Cdkn2b are expressed at
very high levels in day 1 BC and SM cells under normal conditions
Fig. 6. AP-1 is required for de novo TEAD4 binding during differentiation
of HB to HE. (A) Experimental setup: dnFOS ESCs were differentiated into
EBs FLK1+ cells and purified and cultured for 24 h under blast culture
conditions with and without 1 µg/ml DOX. Cells of complete cultures were
double crosslinked and chromatin was used for TEAD4 ChIP followed by
genome-wide sequencing. (B) Overlap of TEAD4 ChIP-seq peaks in DOX-
treated and untreated day 1 BC cells. (C) Enriched transcription factor-binding
motifs within TEAD4 ChIP-seq peaks from DOX-treated and untreated
samples using HOMER de novo motif discovery analysis. (D) TEAD4 ChIP-
seq signal from DOX-treated and untreated cells (left), TEAD and AP1 motif
presence (middle) and day 1 BC DOX/untreated gene expression fold change
(right) ordered by increasing DOX/untreated TEAD4 ChIP-seq signal. Classes
of peaks are indicated on the left and defined using cut-offs of ±1 log2 fold
change, with class-specific average profiles as well as a boxplot showing gene
expression fold change at the bottom. (E) JUN and FOS signals (left) and the
presence of FOS:JUN intersecting peaks, and JUN- and FOS-only peaks
(right) ordered as in D. Bottom: average profiles for peak presence for classes
defined in (D). (F) Representative genome browser screenshot of the
Lamc2 locus showing TEAD4 loss at AP-1 binding sites following dnFOS
induction.
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(Fig. 3); a lower expression of these genes upon AP-1 inhibition
would preferentially enhance the proliferation of SM cells compared
with HE or HP cells. However, we found that the relative proportion
of HE2 cells and not SM cells was increased. Furthermore, after
only 1 day of blast culture, when cell numbers ±DOX were
identical, we already observed reduced proportions of SM cells. In
addition, our gene expression analyses using purified cells show
clearly that the shift in balance between vascular and hemogenic fate
is based on true alterations in gene expression and not just a change
in proliferation.
Among the genes that require AP-1 for their induction, we
identified TFs, ligands, membrane receptors, cytoskeleton and
extracellular matrix proteins (Table S6). However, our data also
show that AP-1 is not a cell fate-deciding factor, but plays a role in
modulating cell fate decisions, most likely in concert with true
master regulators such as RUNX1. We suggest that signalling-
responsive TFs boost the expression of genes that actually define a
cell, such asmetabolic genes, extracellularmatrix and focal adhesion
genes, and other effector genes. One of these genes encodes the
tyrosine kinase AXL (O’Bryan et al., 1991). AXL has been shown to
be involved in vasculogenesis, both together with its ligand GAS6
and also ligand independently through VEGFA-VEGFR2 crosstalk
and subsequent PI3K activation (Melaragno et al., 1999; Ruan
and Kazlauskas, 2012). Thus, reduced Axl expression leads to a
compromised response to VEGFA and in return to attenuated
endothelial function. Another genewe have identified as beingAP-1
dependent encodes the transcription factor Wilms’ tumour 1 (WT1)
(Call et al., 1990; Gessler et al., 1990). This zinc-finger protein is
known to be essential for blood vessel formation, particularly for
coronary vessels (Duim et al., 2015; Katuri et al., 2014).
TEAD requires AP-1 to activate vascular genes in the
hemogenic endothelium
We have previously shown that the interaction between TEAD and
YAP is absolutely required for hematopoietic specification (Goode
et al., 2016). An important finding of our study is therefore that AP-
1-dependent transiently expressed vascular genes in the HE are
bound by both AP-1 and TEAD4. During HB differentiation (day 1
BC) and in HE1 cells, TEAD4 requires AP-1 to be recruited to joint
binding sites, indicating a crosstalk between AP-1 (MAPK and
others) and Hippo signalling pathways. In HB cells, these regulatory
elements are not yet bound by TEAD4, although TEAD4 binding is
present at other genomic sites at this developmental stage. We were
unable to ChIP JUN in FLK1+ cells (data not shown) as Fos is
expressed at only low levels, but is then upregulated in the blast
culture (Fig. S1F), suggesting that, in differentiating HB cells, AP-1
becomes active, recruits TEAD4 and activates gene expression. In
HE2 cells, when a hematopoietic fate is acquired in response to the
upregulation of Runx1, these genes are then repressed. Expression
remains low in HP cells and AP-1 and TEAD footprints are no
longer detectable. In a recent report, an early hemogenic precursor
cell type in mammalian placentas was identified and its
transcriptome was studied (Pereira et al., 2016); it was found that
the genes specific for hemogenic precursors are linked to AP-1-,
TEAD-, TCF- and GATA motifs, supporting the findings of our
digital footprinting experiments, which provides direct evidence
that these sites are occupied.
AP-1- and TEAD4-binding cis-regulatory elements form
signalling hubs in the hemogenic endothelium
Only recently have insights been gained into the role of signalling
pathways involved in embryonic blood specification. For example,
pro-inflammatory cytokines includingTNFα and IFNγwere reported
to promote HSC emergence by acting either upstream or downstream
of Notch (Espín-Palazón et al., 2014; He et al., 2015; Li et al., 2014;
Sawamiphak et al., 2014). WNT signalling via β-catenin is essential
for the generation of the hemogenic endothelium (Ruiz-Herguido
et al., 2012). Catecholamines from the sympathetic nervous system
are important components of the developingHSCmicroenvironment
(Fitch et al., 2012) and BMP4 signalling leads to a SMAD1/5-
mediated repression of Erk transcription in HE cells, implying a role
formitogen-activatedprotein kinase (MAPK) signalling in these cells
(Zhang et al., 2014). The specification of HSCs from the hemogenic
endothelium is a tightly regulated biological process that is controlled
by dynamic changes of signalling and TF activity. The HE is a
heterogeneous tissue in which only a fraction of cells commits to
blood while others remain part of the endothelial layer and may be
important for providing signals to the microenvironment to support
the EHT (Thambyrajah et al., 2016).Our digital footprinting analyses
suggest that HE-specific occupied binding sites form signalling hubs
that bind TFs responding to different signalling pathways, all of
which impact on hematopoietic specification (Kim et al., 2014) and
which are becoming decommissioned after the EHT. We propose a
model inwhich various stimuli regulate the expression of the same set
of genes but via different factors: WNT signalling via TCFs, Hippo
signalling through TEADs, TGFβ and BMP signalling through
SMADs, calcium signalling through NFAT and MAPK/cyclic AMP
signalling through AP-1, ATFs and CREB. It remains unknown,
however, whether all of these signals are active simultaneously in one
cell or if subpopulations of HE cells respond to individual signals at a
given time point.
In conclusion, our bottom-up strategy identifies subtle and varied
roles for AP-1 transcription factor family members during
embryonic blood development. Future work will determine how
different signalling pathways regulate the transcriptional activity of
genes associated with signalling hubs.
MATERIALS AND METHODS
Construction of p2lox-dnFOS plasmid, ESC transfection, culture
and differentiation
The Flag-tagged dominant-negative FOS (dnFOS) construct was PCR
amplified from CMV plasmid [CMV500-8584hep-fosLZ(MO)], A-FOS
[kindly provided by Charles Vinson, National Cancer Institute, Bethesda,
USA (Olive et al., 1997)], and HindIII and NotI sites were introduced. The
GFP of the p2lox plasmid [kindly provided byMichael Kyba, Lillehei Heart
Institute, University of Minnesota, USA (Kyba et al., 2002)] was exchanged
for Flag-tagged dnFOS.
A2lox ESCs [a gift from Michael Kyba (Kyba et al., 2002)] or Bry-GFP
ESCs were cultured and transfected as described previously (Gilmour et al.,
2014; Lichtinger et al., 2012; Regha et al., 2015). ESCs were differentiated
as described previously (Gilmour et al., 2014; Lancrin et al., 2010;
Lichtinger et al., 2012). Further details can be found in the supplementary
Materials and Methods.
Methylcellulose hematopoietic progenitor colony assay
Floating progenitors were harvested from the supernatant of day 3 blast
cultures ±DOX, counted and plated in triplicates at 10,000 cells per ml of
MethoCult methylcellulose (Stem Cell Technologies, M3434) without
DOX. After 7-10 days, colonies were counted and classified as BFU-E,
CFU-Mix or CFU-GM.
Giemsa staining
Individual colonies of methylcellulose cultures were picked, washed in PBS
and immobilized on microscope slides by cytospin (4 min, 800 rpm,
Shandon Cytospin 3). Cells were fixed with methanol for 1 min, air-dried,
Giemsa-stained for 3 min (Sigma, GS500) and analysed by microscopy.
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Flow cytometry and FACS sorting
Cells at the developmental stages indicated were harvested and stained,
and DNA content was measured. Further details can be found in the
supplementary Materials and Methods
RNA extraction, RT-qPCR and gene expression microarray
analyses
For RNA extraction, cell pellets were re-suspended in Trizol (Invitrogen)
and purified according to the manufacturer’s protocol. The microarrays used
were Agilent SurePrint G3 Mouse 8X60K microarrays (catalogue number
G4852A-028005).
cDNA was prepared from the mRNAs using MMLV-RT (Promega
M170A) and oligo dT primers according to the manufacturer’s
recommendations. Real-time PCR was performed with SYBR Green PCR
master mix (Life Technologies, 4309155) and in an ABI Stepone real-time
PCR machine. Further details and primer sequences can be found the
supplementary Materials and Methods.
Immunofluorescence staining
dnFOS ESCs were cultured for 2 days on glass cover slips in 24-well plates
with MEFs and ESC medium, treated and incubated with primary and
secondary antibodies. Further details can be found in the supplementary
Materials and Methods.
Western blotting
Protein extracts in Laemmli buffer were separated on 4-20% pre-cast
gradient SDS-PAGE gels (Biorad) and western blots prepared by wet
transfer onto nitrocellulose membrane. Further details can be found in the
supplementary Materials and Methods.
Chromatin immunoprecipitation (ChIP) and library preparation
Cells (2×106 to 5×106) were harvested and washed in PBS before a two-step
crosslinking procedure. First, proteins were crosslinked by incubating cells for
45 min at room temperature in PBS supplemented with 0.83 mg/ml Di
(N-succinimidyl) glutarate (DSG, Sigma 80424). After three PBS washes,
formaldehyde crosslinking of proteins and DNA was carried out for 10 min at
room temperature at a concentration of 1% formaldehyde (Pierce) in PBS.
Formaldehyde was quenched by adding glycine to a final concentration of
100 mM and crosslinked cells were washed twice in ice-cold PBS. Nuclei
isolation, sonication andChIPwere performed as previously described (Gilmour
et al., 2014; Lichtinger et al., 2012; Regha et al., 2015). Further details and ChIP
primer sequences can be found in the supplementary Materials and Methods.
DNaseI digestion and library preparation
DNaseI digestion and libraries were prepared as described previously
(Ptasinska et al., 2012) and deep sequencing was carried out on Illumina
HiSeq2000.
Luciferase assay
RAW cells were grown in DMEM medium supplemented with 10% FCS,
penicillin and streptomycin, and plasmids were transfected using Invitrogen
Lipofectamine according to the manufacturer’s guidelines. Samples were
prepared using Promega DnaI Luciferase Reporter Assay. Further details
can be found in the supplementary Materials and Methods.
Data accessibility, processing and analysis
High-throughput sequencing processing, peak detection and generation
of coverage tracks
Briefly, alignment of reads was performed using bowtie; peak detection and
coverage track generation with macs14. Further details can be found in the
supplementary Materials and Methods.
ChIP-seq and DNaseI-seq rankings, heatmaps and average profiles
Briefly, ChIP-seq, DNaseI-seq heatmaps and average profiles were derived
from ranked regions using tag count retrieved ±1000bp around summits via
HOMER. Further details can be found in the supplementary Materials and
Methods.
Motif discovery, heatmaps and average profiles
In brief, motif discovery, heatmaps and average profiles were carried out
using HOMER. Further details can be found in the supplementary Materials
and Methods.
Gene ontology analyses
Gene ontology (GO) analyses (biological process and KEGG pathway
ontology classes) were performed using DAVID (Huang da et al., 2009) for
all figures except Fig. 4.
Venn diagrams
Venn diagrams using gene names were derived using BioVenn (Hulsen
et al., 2008). For high-throughput sequencing peaks, the makeVennDiagram
function of the ChIPpeakAnno R package (Zhu et al., 2010) was used,
which was also used to compute hypergeometric p-values of intersections.
Further details can be found in the supplementary Materials and Methods.
Digital genomic footprinting
Digital genomic footprinting was performed using Wellington (Piper et al.,
2013) using standard parameters. Further details can be found in the
supplementary Materials and Methods.
Motif co-occurrence clustering
Essentially, motif co-occurrence clustering was performed on enrichments
of co-occurring footprinted motifs over a random background, using cluster
3.0. Further details can be found in the supplementary Materials and
Methods.
Gene set enrichment analyses
Gene-set enrichment analyses were performed with the GSEA analysis
suite (Subramanian et al., 2005). Further details can be found in the
supplementary Materials and Methods.
K-means clustering
Expression values of the closest gene were recovered for FOS:JUN co-
bound peaks. K-means clustering was performed aiming for seven gene
glusters using cluster 3.0 using -g 2 -k 7 -na -ng as parameters.
Motif distances
In summary, distributions of distances between the TEAD motif end and
AP-1 motif start coordinates were computed and plotted using HOMER and
R. Further details can be found in the supplementary Materials and
Methods.
Microarray data analysis
Microarray data analysis was performed as previously described (Lichtinger
et al., 2012), using the limma R package. Further details can be found in the
supplementary Materials and Methods.
Public datasets
The HB DNaseI-seq and TEAD4 ChIP-seq (Goode et al., 2016), as well as
mast cell FOS ChIP-seq (Calero-Nieto et al., 2014) datasets were
downloaded as SRA archives from the Gene Expression Omnibus
accession numbers GSM1692782, GSM1968747 and GSM1167585,
respectively. These were converted to fastq via sra-toolkit 2.5.2 (Leinonen
et al., 2011). These datasets were processed in the same way as other high-
throughput sequencing samples from this study.
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